Name:
A video summary of the HIMALAYA study PLSP: Tremelimumab and Durvalumab for Unresectable Hepatocellular Carcinoma
Description:
A video summary of the HIMALAYA study PLSP: Tremelimumab and Durvalumab for Unresectable Hepatocellular Carcinoma
Thumbnail URL:
https://cadmoremediastorage.blob.core.windows.net/c1b4ef56-ad66-476b-a129-8bf674fa583f/videoscrubberimages/Scrubber_42.jpg
Duration:
T00H02M31S
Embed URL:
https://stream.cadmore.media/player/c1b4ef56-ad66-476b-a129-8bf674fa583f
Content URL:
https://cadmoreoriginalmedia.blob.core.windows.net/c1b4ef56-ad66-476b-a129-8bf674fa583f/VJBM-2023-0016 HIMALAYA Video v0.3 (1).mp4?sv=2019-02-02&sr=c&sig=bKtKnsoM0eXjCDuffIuxukpe38kMnvDWaXi%2BZ0rTz%2Bk%3D&st=2025-04-24T06%3A33%3A35Z&se=2025-04-24T08%3A38%3A35Z&sp=r
Upload Date:
2025-04-01T00:00:00.0000000
Transcript:
Language: EN.
Segment:1 Unresectable HCC + How do tremelimumab and durvalumab work?.
SPEAKER: HCC is the most common type of liver cancer. Many people are diagnosed with HCC that cannot be removed with surgery, known as unresectable HCC. Before the introduction of immunotherapy, sorafenib had been the main treatment for people with unresectable HCC. Tremelimumab and durvalumab are types of cancer treatment called immunotherapy. They work in different ways to help the immune system fight cancer.
Segment:2 How was the HIMALAYA study conducted?.
SPEAKER: HIMALAYA compare tremelimumab plus durvalumab, known as STRIDE, versus sorafenib, or durvalumab alone versus sorafenib in unresectable HCC. Participants continue treatment until they experience tumor growth, experience side effects that cause them to stop treatment, wanted to leave the study, or died. In some cases, participants could continue treatment after their cancer progressed if the investigator decided they were benefiting from treatment.
Segment:3 What were the results of the study?.
SPEAKER: Over half of participants remained in the study for over 32 months. After 36 months of treatment, more participants who took STRIDE or durvalumab were alive then those who took sorafenib, and there was a survival benefit with STRIDE versus sorafenib, regardless of participants characteristics at the start of the study. In HIMALAYA, participants who took STRIDE were less likely to die than those who took sorafenib.
SPEAKER: Participants who took STRIDE or durvalumab maintained their quality of life for longer than participants who took sorafenib. Overall, STRIDE or durvalumab were less likely than sorafenib to cause side effects related to treatment. The most common side effects considered to be related to the treatment being studied were consistent with what is expected for these types of treatments.
SPEAKER: Fewer participants who took STRIDE or durvalumab stopped treatment due to side effects related to treatment than those who took sorafenib. STRIDE and durvalumab are promising new treatments that are approved for unresectable HCC in different countries across the globe.
Segment:4 Closing.
SPEAKER: [MUSIC PLAYING]
